Middle East and Africa Lung Cancer Therapeutics Market – Industry Trends and Forecast to 2026

  • Healthcare IT
  • Published Report
  • Apr 2019
  • MEA
  • 350 Pages
  • No of Tables: 30
  • No of Figures: 90

Middle East and Africa Lung Cancer Therapeutics Market By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumors, Mediastinal Tumors, Mesothelioma, Chest Wall Tumors), Molecule Type (Small Molecules, Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors, Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy, Others), Therapy Type (Single Drug Therapy, Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online, Others), Country (South Africa, Rest of Middle East & Africa) – Industry Trends and Forecast to 2026

The lung cancer is type of cancer which decreases the efficiency of lungs to supply oxygen to the bloodstream. This is one of the most forms of cancers which accounts for the highest mortality rates. The lung cancer can be categorized as an uncontrolled growth of cell in the lungs. The main cause of lung cancers is pipes, cigarette smoking, cigar smoking, and asbestos exposure. Almost around 80.0% of the total lung cancers are non-small cell lung cancer. This kind of cancer is distinguished by their size as they are seen under the microscope. The most common symptoms of lung cancer are coughing, weight loss, chest pains, and shortness of breath. Lung cancers can be treated by various types of therapies like vaccines, radiation therapy, chemotherapy, and immunotherapies.

Middle East and Africa lung cancer therapeutics market is expected to register a healthy CAGR in the forecast period of 2019 to 2026.

Segmentation: Middle East and Africa Lung Cancer Therapeutics Market

Middle East and Africa lung cancer therapeutics market is segmented into seven notable segments which are cancer type, molecule type, drug class, treatment type, therapy type, end user, distribution channel.

  • On the basis of cancer type, the market is segmented into non-small cell lung cancer, metastatic lung cancer, mesothelioma, chest wall tumors, pulmonary neuroendocrine tumors, mediastinal tumors
  • On the basis of molecule type, the market is segmented into small molecules, biologics
  • On the drug class, the market is segmented into alkylating agents, antimetabolites, mitotic inhibitors, multikinase inhibitors, EGFR inhibitors, others
  • On the basis of treatment type, the market is segmented into radiation therapy, chemotherapy, targeted therapy, immunotherapy, and other drugs
  • On the basis of therapy type, the market is segmented into single drug therapy, combination therapy
  • On the basis of end user, the market is segmented into hospitals, specialty clinics, homecare, others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online and others

Competitive Analysis: Middle East and Africa Lung Cancer Therapeutics Market

Some of the prominent players operating in this market are Takeda Pharmaceutical Company Limited, ONO PHARMACEUTICAL CO., LTD., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company., AstraZeneca, Boehringer Ingelheim International GmbH, Merck & Co., Inc., CELGENE CORPORATION, AMGEN INC., Sanofi, Johnson & Johnson Services, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., ALLERGAN, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., and many others.

Recent Development

  • In March 2019, Eli Lilly and Company participated in Cowen and Company’s 39th Annual Health Care Conference which was held on March 11, 2019. This would help the company to enhance its customer base.
  • In January 2019, the company entered into a merger agreement with the Bristol-Myers Squibb Company under which the Bristol-Myers Squibb will be acquiring Celgene in a stock and cash transaction with the equity value of around USD 74 billion. This would help in the expansion of the product portfolio of the companies.
  • In February 2018, GSK and Merck KGaA, Darmstadt, Germany has developed M7824. This is a novel immunotherapy which has potential in treating multiple difficult-to-treat cancer such as non-small cell lung and biliary tract cancers. This increases the company’s product line for this market.

Research Methodology: Middle East and Africa Lung Cancer Therapeutics Market

Primary Respondents: Key Opinion Leaders (KOL’s): Manufacturer, Healthcare Professionals, Doctors, Nurses, Medical practitioners. Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and, National Sales Managers.


SKU-

LIST OF TABLES MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET

TABLE 1 PREVALENCE OF SUBTYPES OF LUNG CARCINOMA IN SMOKERS AND NEVER-SMOKERS TABLE 2 COST OF TARGETED THERAPIES FOR THE TREATMENT OF NSCLC (2018) TABLE 3 COST OF IMMUNOTHERAPIES FOR THE TREATMENT OF NSCLC (2018) TABLE 4 SOME OF THE PIPELINE LUNG CANCER DRUGS ARE MENTIONED IN THE BELOW TABLE 5 AVERAGE COST OF LUNG CANCER TREATMENT (2018) TABLE 6 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 7 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 8 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 9 MIDDLE EAST & AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 10 MIDDLE EAST & AFRICA METASTATIC LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 11 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 12 MIDDLE EAST & AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 13 MIDDLE EAST & AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 14 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 15 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 16 MIDDLE EAST & AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 17 MIDDLE EAST & AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 18 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 19 MIDDLE EAST & AFRICA MESOTHELIOMA IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 20 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 21 MIDDLE EAST & AFRICA SMALL MOLECULE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 22 MIDDLE EAST & AFRICA BIOLOGICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 23 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 24 MIDDLE EAST & AFRICA ALKYLATING AGENTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 25 MIDDLE EAST & AFRICA ANTIMETABOLITES IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 26 MIDDLE EAST & AFRICA MITOTIC INHIBITORS PRODUCTS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 27 MIDDLE EAST & AFRICA MULTIKINASE INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 28 MIDDLE EAST & AFRICA EGFR INHIBITORS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 29 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 30 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 31 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 32 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 33 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 34 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 35 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 36 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 37 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 38 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 39 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 40 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 41 MIDDLE EAST & AFRICA SINGLE DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 42 MIDDLE EAST & AFRICA COMBINATION DRUG THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 43 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 44 MIDDLE EAST & AFRICA HOSPITALS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 45 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 46 MIDDLE EAST & AFRICA HOMECARE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 47 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 48 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 49 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 50 MIDDLE EAST & AFRICA RETAIL PHARMACY IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 51 MIDDLE EAST & AFRICA ONLINE IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 52 MIDDLE EAST & AFRICA OTHERS IN LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2017-2026 (USD MILLION) TABLE 53 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY COUNTRY, 2017-2026 (USD MILLION) TABLE 54 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 55 MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 56 MIDDLE EAST & AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 57 MIDDLE EAST & AFRICA CHEST WALL TUMOR IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 58 MIDDLE EAST & AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 59 MIDDLE EAST & AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 60 MIDDLE EAST & AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 61 MIDDLE EAST & AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 62 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 63 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 64 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 65 MIDDLE EAST & AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 66 MIDDLE EAST & AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 67 MIDDLE EAST & AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 68 MIDDLE EAST & AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 69 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 70 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 71 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 72 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 73 SOUTH AFRICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 74 SOUTH AFRICA SALIVARY GLAND-TYPE LUNG CARCINOMA IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 75 SOUTH AFRICA CHEST WALL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 76 SOUTH AFRICA PULMONARY NEUROENDOCRINE TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 77 SOUTH AFRICA SMALL-CELL LUNG CANCER IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 78 SOUTH AFRICA CARCINOID TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 79 SOUTH AFRICA MEDIASTINAL TUMORS IN LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION) TABLE 80 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY MOLECULE TYPE, 2017-2026 (USD MILLION) TABLE 81 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION) TABLE 82 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 83 SOUTH AFRICA CHEMOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 84 SOUTH AFRICA RADIATION THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 85 SOUTH AFRICA TARGETED THERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 86 SOUTH AFRICA IMMUNOTHERAPY IN LUNG CANCER THERAPEUTICS MARKET, BY TREATMENT TYPE, 2017-2026 (USD MILLION) TABLE 87 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY THERAPY TYPE, 2017-2026 (USD MILLION) TABLE 88 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY END USER, 2017-2026 (USD MILLION) TABLE 89 SOUTH AFRICA LUNG CANCER THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION) TABLE 90 MIDDLE EAST & AFRICA LUNG CANCER THERAPEUTICS MARKET, BY CANCER TYPE, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions